Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide and SNAC concentrations in breastmilk
NCT04817644Phase 1Completed
- Sponsor
- Novo Nordisk
- Start
- Sep 2021
- Primary completion
- May 2023
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of semaglutide in type 2 diabetes mellitus (T2DM), sponsored by Novo Nordisk. Primary endpoints: Area under the semaglutide milk concentration-time curve and Area under the SNAC milk concentration-time curve. Started Sep 2021; status: completed.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT04817644.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04817644.